Blumenthal-Barby J

INTRODUCTION Biological factors such as age, renal and hepatic function, body surface area or weight and baseline blood counts are universally taken into account when designing and adjusting treatment for haematological malignancies (HM). However, despite increasingly recognized differences in disease risk, prognosis and treatment toxicity between males and females, sex and gender are rarely taken into account in treatment planning for these diseases.

ASD autism spectrum disorder DMD Duchenne muscular dystrophy EDA electrodermal activity HRV heart rate variability PPG photoplethysmography RTT Rett syndrome SMA spinal muscular atrophy SV95C stride velocity 95th centile What this paper adds Recent advancements in wearable sensors highlight their potential to transform the diagnosis, monitoring, and management of paediatric neurological conditions. More research is needed to validate the effectiveness and clinical impact of wearable sensors.

To investigate how to protect participants in the artificial womb technology (AWT) human trials. We compared randomized controlled trials and single arm trials to understand which trial design best balances the interests of science and participants. We also compared AWT trials with comparable settings to understand how to protect participants. Randomized trials might fail in reaching a sizeable sample, which could pointlessly expose participants to risks.